Clinical applications of centrally acting agents in male sexual dysfunction.
Currently available agents for erectile dysfunction (ED) share the same mechanism of action and pharmacologic properties. Therefore, they share the same limitations, including a principal focus on erection as an end-organ process. One of the relatively unexplored areas of research has been the potential for centrally acting agents to improve male sexual response. A variety of neurohormones and neurotransmitter systems are involved in the male sexual response, including testosterone, dopamine, serotonin and the melanocortin systems. Investigations to determine the utility of centrally acting agents as monotherapy or adjunctive therapy in men with ED or other forms of sexual dysfunction are underway. Bremelanotide, a melanocortin agonist, has been tested in men with ED and may prove to be one of the first centrally acting agents to have clinical utility in male sexual dysfunction.
Tulane University Medical Center, New Orleans, LA 70112, USA. whellst@tulane.edu
W J G
WJ
Hellstrom
D018663:Adrenergic Agents / Q000627:therapeutic use; D002491:Central Nervous System Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D053486:Melanocortins / Q000627:therapeutic use; D012701:Serotonin / Q000378:metabolism; D012735:Sexual Dysfunction, Physiological / Q000188:drug therapy* / Q000378:metabolism
D018663:Adrenergic Agents; D002491:Central Nervous System Agents; D053486:Melanocortins; D012701:Serotonin